Skip to main content
Disc Medicine, Inc. logo

Disc Medicine, Inc. — Investor Relations & Filings

Ticker · IRON ISIN · US36870G1058 US Manufacturing
Open in API
Filings indexed 690 across all filing types
Latest filing 2024-06-14 Director's Dealing
Country US United States of America
Listing US IRON

About Disc Medicine, Inc.

https://www.discmedicine.com/

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with serious hematologic diseases. The company's research focuses on fundamental pathways of red blood cell biology to address a range of disorders. Its pipeline includes bitopertin, an investigational therapy for erythropoietic protoporphyria (EPP) for which a New Drug Application has been submitted for accelerated approval. Other clinical-stage programs are evaluating treatments for myelofibrosis-associated anemia and other conditions involving ineffective erythropoiesis.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-06-14 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, reporting the submission of matters to a vote of security holders at the company's 2024 Annual Meeting of Stockholders. It details the voting results for director elections and ratification of the independent auditor. The content focuses on official voting results from the Annual Meeting, not the meeting materials or presentations themselves. The document length is 4232 characters, which is relatively short and consistent with a voting results announcement rather than a full report or presentation. Therefore, this filing fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-06-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 14, 2024. It announces the entry into a material definitive agreement related to an underwritten offering of common stock, including details about the offering size, price, and expected proceeds. It also references the underwriting agreement and related exhibits. The content focuses on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The primary subject is a capital raising event, which fits the Capital/Financing Update category (CAP). The document length is about 5,454 characters, which is sufficient to be the actual report rather than a mere announcement of a report. Therefore, the correct classification is Capital/Financing Update (CAP).
2024-06-14 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a public offering of common stock. It includes detailed information about the offering, underwriting, risk factors, use of proceeds, and other related disclosures. This type of document is a capital markets filing that updates or supplements a registration statement and provides terms of a securities offering. It is not an annual or quarterly report, earnings release, management discussion, or any other report type. It is specifically related to financing activities and capital raising. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full prospectus supplement, not just an announcement or a brief notice.
2024-06-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 14, 2024. It announces updated clinical trial data and a corporate presentation related to ongoing drug studies. The document includes a press release and an investor presentation as exhibits. The content focuses on disclosure of recent data and a webcast event rather than detailed financial results or comprehensive financial statements. The document is not a full annual or quarterly report, audit report, or earnings release. It is primarily a regulatory announcement of new data and corporate presentation updates. Given the nature of the filing (Form 8-K) and the content, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-06-14 English
4
Director's Dealing
2024-06-05 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.